How does ipamorelin differ from ghrelin?

Ipamorelin is a synthetic peptide that mimics ghrelin's action at the GHSR-1a receptor. While both stimulate GH release, ghrelin has broader physiological roles, including appetite regulation. Ipamorelin is designed for more selective action, primarily stimulating GH without significantly affecting feeding or cortisol, unlike ghrelin or many other GHRPs.

Can ipamorelin increase muscle mass?

By increasing GH and subsequent IGF-1 levels, ipamorelin can theoretically support muscle protein synthesis and aid in muscle preservation, particularly in contexts of age-related decline. However, its direct impact on significant muscle hypertrophy in healthy resistance-trained individuals is not as pronounced as anabolic steroids, and more long-term data is needed for definitive claims.

Is ipamorelin safe for long-term use?

The long-term safety profile of ipamorelin, especially in healthy individuals for anti-ageing purposes, has not been established through large, controlled clinical trials. While short-term studies show a favourable side-effect profile regarding cortisol and prolactin, potential effects of chronic GH/IGF-1 elevation necessitate caution and medical supervision.

What are the common side effects of ipamorelin?

Common side effects are generally mild and related to GH elevation, including headache, dizziness, and injection site reactions. Some individuals may experience temporary water retention or mild joint discomfort. It is specifically designed to minimise the cortisol and prolactin elevations seen with other GHRPs, leading to fewer associated side effects.

How quickly does ipamorelin work?

Ipamorelin acts rapidly, with peak growth hormone levels typically observed within 30 to 60 minutes after administration. Its effect on GH is acute and pulsatile. While GH spikes quickly, the resulting increase in IGF-1 is more gradual and requires sustained administration to become clinically significant.

Research Library

The synthesized longevity record.

1,200+ peer-reviewed studies indexed, graded and cross-referenced. Updated daily with the most consequential findings in healthspan science.

Grade CPeptides · 12 min

Ipamorelin's Mechanism of Action: Unpacking Growth Hormone Secretion

This paper examines the precise molecular and physiological mechanisms through which ipamorelin stimulates growth hormone release, detailing its selective interplay with ghrelin receptors.

Grade BSupplements · 12 min

Rhodiola Rosea: Unpacking its Mechanism of Action for Stress Resilience

This paper investigates the molecular mechanisms through which Rhodiola rosea exerts its adaptogenic effects, focusing on HPA axis modulation, neuroprotection, and cellular stress responses.

Grade ANAD+ · 9 min

NMN vs NR: Which NAD+ Precursor Wins for Adult Restoration?

Head-to-head review of nicotinamide mononucleotide and nicotinamide riboside — pharmacokinetics, NAD+ uplift, human trial endpoints, and dosing strategy.

Grade AFasting · 11 min

Time-Restricted Eating and Metabolic Flexibility: The 2026 Evidence

What 14 years of randomized trials reveal about TRE windows, circadian alignment, insulin sensitivity, and lean mass preservation.

Grade BRapamycin · 14 min

Intermittent Rapamycin in Healthy Adults — The PEARL Trial

Inside the largest randomized trial of low-dose rapamycin for healthspan: dosing schedule, lean-mass and pain outcomes, immune signals, and what it does and does not prove.

Grade BGLP-1 / GIP / Glucagon · 13 min

Retatrutide Beyond Weight Loss: Cardiometabolic and Longevity Signals

The first triple GIP/GLP-1/glucagon agonist is generating obesity, hepatic, and cardiometabolic data that already exceed any prior incretin — and points to a broader longevity signal.